Filing Flows › Health Care › Dyadic International (DYAI)
Dyadic International (DYAI) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 12, 2026 · Dyadic International (DYAI) Q2 2026 earnings results →
Q2 2026 Revenue down 1% year over year to $961K · 221¢ of every $1 of revenue lost · operating margin -213.7%
Dyadic International made $961K in Q2 2026 (-0.6% Y/Y): Grant $837K, Research and Development $124K. Operating margin -213.7%, net loss $2.1M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 12, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.0M in Q2 2026, down 1% year over year and down 13% from the previous quarter. Grant was the largest line at 87% of revenue. Research and Development lost $90K year over year (down 42%), 1631% of the total change.
Operating costs exceeded revenue by $2.1M, an operating margin of -213.7%. Total costs grew 12% against a revenue fall of 1%. The fastest-growing cost line was Cost of revenue (+60%). The quarter ended with a net loss of $2.1M, wider than the previous quarter's $2.0M loss.
Operating cash flow was −$1.8M. Non-cash charges added back $144K of share-based compensation. Working capital and other items added $161K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 12, 2026 | $961K | -0.6% | -213.7% | −$2.1M | −$1.8M |
| Q1 2026 | 10-Q | May 13, 2026 | $1.1M | +182% | -171.3% | −$2.0M | −$2.0M |
| Q4 2025 | 10-K | Mar 25, 2026 | $566K | -31% | -271.6% | −$1.6M | −$1.8M |
| Q3 2025 | 10-Q | Nov 12, 2025 | $1.2M | -40% | -165.3% | −$2.0M | −$1.9M |
| Q2 2025 | 10-Q | Aug 13, 2025 | $967K | +150% | -178.9% | −$1.8M | −$130K |
| Q1 2025 | 10-Q | May 14, 2025 | $394K | +18% | -508.8% | −$2.0M | −$1.9M |
| Q4 2024 | 10-K | Mar 26, 2025 | $817K | +19% | -187.2% | −$1.6M | −$696K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Dyadic International
Dyadic Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life sciences, food and nutrition, and bio-industrial markets. These high-quality proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic’s Dapibus™ and C1 expression systems support flexible, cost-effective manufacturing, and are the foundation of a growing portfolio of commercial and partnered programs.
In its own words, from its 8-K, filed Aug 12, 2026.
Dyadic International against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -0.6% against the peers' median +11%. Operating margin: -213.7% against the peers' median 35.8%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| DYAI Dyadic International | Q2 2026 | $961K | -0.6% | -213.7% |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: Dyadic International 10-Q on SEC EDGAR · CIK 1213809 · Biological Products, (No Diagnostic Substances)
13F: who owns DYAI and who is buying
More on DYAI
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results